TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06658353: Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06658353 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06658353 Rescue Dossier →